Squaramide CB1 Allosteric Modulators With Fewer Adverse Effects

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current medications for substance abuse disorders, particularly those targeting the cannabinoid 1 receptor (CB1R), have limited long-term efficacy and are associated with adverse side effects, necessitating the development of compounds that can modulate CB1R activity with improved pharmacokinetic properties and reduced side effects.

Innovation Solution

Development of squaramide-based CB1R allosteric modulator compounds, including specific chemical structures and their pharmaceutically acceptable salts, to target CB1R for treating conditions such as obesity, substance abuse, and other diseases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If CB1R inverse agonist/antagonist (rimonabant) is used to treat obesity, then weight loss and metabolic improvement are achieved, but adverse effects including suicidal ideation occur

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidadverse effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the fundamental parameter of receptor modulation from inverse agonism/antagonism to positive allosteric modulation. This parameter change allows the compound to enhance endocannabinoid signaling in a controlled manner, achieving therapeutic effects on obesity and metabolic disorders while avoiding the severe adverse effects associated with CB1R inverse agonists like rimonabant.

Inventive Principle:

Principle #35Parameter changes

2Duration of action of moving object

If CB1R inverse agonist/antagonist is used for substance abuse treatment, then craving reduction may be achieved, but long-term abstinence rate remains low and side effects occur

Engineering Contradiction:

Improvelong-term abstinenceVSAvoidtreatment efficacy

Core Design Contradiction:

Duration of action of moving objectVSReliability

Solution Approach 1:

The patent introduces positive allosteric modulators as intermediary compounds that indirectly enhance CB1R signaling through endocannabinoids rather than directly activating or blocking the receptor. This intermediary mechanism provides sustained therapeutic effect for substance abuse treatment while improving long-term abstinence rates compared to direct CB1R inverse agonists.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Quantity of substance

If rimonabant is administered for obesity treatment, then appetite suppression and weight loss are achieved, but psychiatric side effects including depression and anxiety occur

Engineering Contradiction:

Improvebody weightVSAvoidpsychiatric side effects

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent inverts the approach to CB1R modulation by using positive allosteric modulators instead of inverse agonists. Rather than blocking CB1R activity to suppress appetite, the invention enhances endocannabinoid-mediated CB1R signaling in a controlled manner, achieving weight loss and appetite control while avoiding psychiatric side effects through the inverted mechanism of action.

Inventive Principle:

Principle #13The other way round (Inversion)

4Ease of operation

If conventional CB1R medications are used for substance abuse, then some relief from withdrawal symptoms is achieved, but one-year abstinence rate is only about 20%

Engineering Contradiction:

Improvewithdrawal symptom reliefVSAvoidabstinence duration

Core Design Contradiction:

Ease of operationVSDuration of action of moving object

Solution Approach 1:

The patent employs dynamic positive allosteric modulators that can adaptively enhance CB1R signaling based on physiological needs and endocannabinoid levels. This dynamic mechanism provides flexible withdrawal symptom relief while promoting sustained long-term abstinence, overcoming the limited duration of action of conventional CB1R medications.

Inventive Principle:

Principle #15Dynamics

Data Source

PatentUS20260062376A1Squaramide derivatives as CB1 allosteric modulators

Publication Date: 2026.03.05 RES TRIANGLE INST

AI summary

Squaramide-based cannabinoid 1 receptor (CB1R) allosteric modulators are described. Exemplary analogs may provide improved potencies and pharmacokinetic properties. Methods of using the analogs to treat diseases mediated by CB1R, such as substance abuse and obesity, are described.